Research ExplorerPublicationsThe chronic liver disease in patients with short bowel syndr...

The chronic liver disease in patients with short bowel syndrome

Standard

The chronic liver disease in patients with short bowel syndrome : etiology and treatment. / Reinshagen, K; Adams, R; Trunk, M; Wessel, L M.

In: MINERVA PEDIATR, Vol. 61, No. 3, 06.2009, p. 273-81.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Reinshagen, K, Adams, R, Trunk, M & Wessel, LM 2009, 'The chronic liver disease in patients with short bowel syndrome: etiology and treatment', MINERVA PEDIATR, vol. 61, no. 3, pp. 273-81.

APA

Reinshagen, K., Adams, R., Trunk, M., & Wessel, L. M. (2009). The chronic liver disease in patients with short bowel syndrome: etiology and treatment. MINERVA PEDIATR, 61(3), 273-81.

Vancouver

Reinshagen K, Adams R, Trunk M, Wessel LM. The chronic liver disease in patients with short bowel syndrome: etiology and treatment. MINERVA PEDIATR. 2009 Jun;61(3):273-81.

Bibtex

@article{37ce4cdb372b401f814d1d5f67b3bc8d,
title = "The chronic liver disease in patients with short bowel syndrome: etiology and treatment",
abstract = "Short bowel syndrome is a life threatening disease with a high mortality and morbidity. Since home parenteral nutrition (PN) has been established, there is an increasing number of patients surviving the acute loss of bowel function. But on the long-time these patients suffer from different complications of PN, with loss of central venous access, recurrent sepsis and finally the syndrome of progressive cholestatic liver disease. Both loss of central venous access and especially the progressive cholestatic liver disease are the limiting factor for the long-term survival of patients suffering from intestinal failure. Interestingly, the pathophysiologic mechanisms of PN induced intrahepatic cholestasis have not been dissolved yet and seem to be of multifactorial genesis. Cholestasis has shown to be associated with prematurity, recurrent sepsis, enteral and PN, especially with lipid emulsions. Enteral feeding and a well-controlled regime of PN lower the incidence of end-stage liver disease and, therefore, has to be optimized in the therapy of these patients.",
keywords = "Anti-Bacterial Agents, Child, Cholagogues and Choleretics, Cholestasis, Drug Therapy, Combination, Enteral Nutrition, Evidence-Based Medicine, Humans, Infant, Newborn, Infant, Premature, Intestine, Small, Liver Diseases, Parenteral Nutrition, Parenteral Nutrition, Home, Practice Guidelines as Topic, Prognosis, Risk Factors, Sepsis, Short Bowel Syndrome, Treatment Outcome, Ursodeoxycholic Acid, Journal Article, Review",
author = "K Reinshagen and R Adams and M Trunk and Wessel, {L M}",
year = "2009",
month = jun,
language = "English",
volume = "61",
pages = "273--81",
journal = "MINERVA PEDIATR",
issn = "0026-4946",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

RIS

TY - JOUR

T1 - The chronic liver disease in patients with short bowel syndrome

T2 - etiology and treatment

AU - Reinshagen, K

AU - Adams, R

AU - Trunk, M

AU - Wessel, L M

PY - 2009/6

Y1 - 2009/6

N2 - Short bowel syndrome is a life threatening disease with a high mortality and morbidity. Since home parenteral nutrition (PN) has been established, there is an increasing number of patients surviving the acute loss of bowel function. But on the long-time these patients suffer from different complications of PN, with loss of central venous access, recurrent sepsis and finally the syndrome of progressive cholestatic liver disease. Both loss of central venous access and especially the progressive cholestatic liver disease are the limiting factor for the long-term survival of patients suffering from intestinal failure. Interestingly, the pathophysiologic mechanisms of PN induced intrahepatic cholestasis have not been dissolved yet and seem to be of multifactorial genesis. Cholestasis has shown to be associated with prematurity, recurrent sepsis, enteral and PN, especially with lipid emulsions. Enteral feeding and a well-controlled regime of PN lower the incidence of end-stage liver disease and, therefore, has to be optimized in the therapy of these patients.

AB - Short bowel syndrome is a life threatening disease with a high mortality and morbidity. Since home parenteral nutrition (PN) has been established, there is an increasing number of patients surviving the acute loss of bowel function. But on the long-time these patients suffer from different complications of PN, with loss of central venous access, recurrent sepsis and finally the syndrome of progressive cholestatic liver disease. Both loss of central venous access and especially the progressive cholestatic liver disease are the limiting factor for the long-term survival of patients suffering from intestinal failure. Interestingly, the pathophysiologic mechanisms of PN induced intrahepatic cholestasis have not been dissolved yet and seem to be of multifactorial genesis. Cholestasis has shown to be associated with prematurity, recurrent sepsis, enteral and PN, especially with lipid emulsions. Enteral feeding and a well-controlled regime of PN lower the incidence of end-stage liver disease and, therefore, has to be optimized in the therapy of these patients.

KW - Anti-Bacterial Agents

KW - Child

KW - Cholagogues and Choleretics

KW - Cholestasis

KW - Drug Therapy, Combination

KW - Enteral Nutrition

KW - Evidence-Based Medicine

KW - Humans

KW - Infant, Newborn

KW - Infant, Premature

KW - Intestine, Small

KW - Liver Diseases

KW - Parenteral Nutrition

KW - Parenteral Nutrition, Home

KW - Practice Guidelines as Topic

KW - Prognosis

KW - Risk Factors

KW - Sepsis

KW - Short Bowel Syndrome

KW - Treatment Outcome

KW - Ursodeoxycholic Acid

KW - Journal Article

KW - Review

M3 - SCORING: Journal article

C2 - 19461571

VL - 61

SP - 273

EP - 281

JO - MINERVA PEDIATR

JF - MINERVA PEDIATR

SN - 0026-4946

IS - 3

ER -